A group of entrepreneurs from Mitsui & Co., LTD., a Japanese TOP trading company, and NovaQuest, a subsidiary company, visited Shenzhen Cell Valley for investigation and exchange
On September 19, Lu Yang, manager of NovaQuest USA, Mr. Muto, general manager of Mitsui Co., LTD. Shenzhen, Li Zhe, manager of Beijing Company, Wang Jiannan, general manager of Shenzhen Faith Investment Management Co., LTD., Chen Lily, assistant general manager, Li Zeen, assistant general manager of Shenzhen Beimei Pharmaceutical Co., LTD., visited Shenzhen Cell Valley. Professor Shi Yuanyuan, chairman and general manager of Shenzhen Cell Valley, Professor Wang Jianxun, chief scientist, Luan Zhishi, director of General Office, Wei Zheng, Assistant chairman, Zhao Lijun, head of Research and development Department, Sun Rui, head of market development Department, warmly received the company, and the two sides had a discussion and exchange on the plan to cooperate in exploring the international market.
First of all, the Chinese and Japanese entrepreneurs, accompanied by Professor Shi Yuanyuan, the chairman, visited the smart exhibition hall and GMP production workshop, research and development laboratory, and initially understood the founding background of the company, the founder team, the history of CAR-T therapy, strategic layout, and the construction of innovative service platform.
At the symposium, by analyzing the international market environment of the cell and gene therapy industry and the pain points existing under the rapid development trend, the chairman Professor Shi Yuanyuan introduced the technological breakthroughs and innovations of Shenzhen Cell Valley in the upstream and downstream aspects of cell and gene therapy. As the only CRO/CDMO one-stop outsourcing service provider that masters industrial retrovirus vector technology (PackRV-SE and other systems) in China, it has completed the effective layout in Shenzhen, Beijing and Zhongshan, and can provide professional and efficient one-stop whole industry chain services from early research and development to carrier design to virus production to cell production to auxiliary declaration. In the future, we will continue to adhere to the corporate purpose of "cells benefit all beings and genes create the future", explore overseas markets, give full play to the advantages of retrovirus vectors in the industrialization of cell therapy drugs, and benefit the majority of cancer patients. As one of the five major trading companies in Japan, Mitsui & Co., Ltd. has diversified business sectors, involving Europe, America, Japan, Southeast Asia and other countries. As a subsidiary of Mitsui & Co., NovaQuest focuses on pharmaceutical investment and has rich experience and channel resources in R&D pipeline investment. Both sides can fully build a bridge of communication and build a platform for sharing resources. Give full play to the advantages of enterprises, deepen cooperation, achieve complementary channels, technologies, products, policies and other aspects, and work together to help the development of cell and gene therapy.
The two sides expressed their expectation for future cooperation, laying a good foundation for future cooperation, providing new possibilities for the treatment and medical progress of difficult diseases such as cancer, and making positive contributions to the high-quality development of the cell and gene therapy industry.
